000			02002 a2200565 4500
005			20250513160628.0
264		0	_c19990714
008			199907s 0 0 eng d
022			_a0269-9370
024	7		_a10.1097/00002030-199818000-00009 _2doi
040			_aNLM _beng _cNLM
100	1		_aBelshe, R B
245	0	0	_aInduction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. _h[electronic resource]
260			_bAIDS (London, England) _cDec 1998
300			_a2407-15 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAIDS Vaccines _xadverse effects
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAvipoxvirus _ximmunology
650	0	4	_aCD8-Positive T-Lymphocytes
650	0	4	_aDouble-Blind Method
650	0	4	_aHIV Antibodies _xblood
650	0	4	_aHIV Envelope Protein gp120 _ximmunology
650	0	4	_aHIV Infections _xprevention & control
650	0	4	_aHIV-1 _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunization Schedule
650	0	4	_aMiddle Aged
650	0	4	_aNeutralization Tests
650	0	4	_aPeptide Fragments _ximmunology
650	0	4	_aProspective Studies
650	0	4	_aT-Lymphocytes, Cytotoxic _ximmunology
650	0	4	_aVaccines, Synthetic
700	1		_aGorse, G J
700	1		_aMulligan, M J
700	1		_aEvans, T G
700	1		_aKeefer, M C
700	1		_aExcler, J L
700	1		_aDuliege, A M
700	1		_aTartaglia, J
700	1		_aCox, W I
700	1		_aMcNamara, J
700	1		_aHwang, K L
700	1		_aBradney, A
700	1		_aMontefiori, D
700	1		_aWeinhold, K J
773	0		_tAIDS (London, England) _gvol. 12 _gno. 18 _gp. 2407-15
856	4	0	_uhttps://doi.org/10.1097/00002030-199818000-00009 _zAvailable from publisher's website
999			_c9837958 _d9837958